Life Biosciences has treated the first participant in a gene therapy trial designed to partially reprogram aged cells as a glaucoma treatment. The approach turns on three genes intended to drive partial reprogramming—maintaining cellular identity while restoring aspects of “youthful” function. The company expects the protein products to support regeneration of optic nerve neurons, which generally do not regenerate in adults. Because partial reprogramming carries theoretical safety concerns, including a potential risk of tumorigenesis, the trial is positioned around safety evaluation while assessing feasibility of the reprogramming mechanism in humans. The first-in-human step follows preclinical animal findings suggesting partial reprogramming can be performed with safety, while acknowledging that risks remain a central question for the field.